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the increasing of CHADS score: 4.6, 8.9 and 18,5 for low, moderate and high stroke 
risk, respectively. The average cost during the index year was around 9,600€ /patient-
years: the main driver was represented by hospitalizations (83%), followed by drugs 
(9%). ConClusions: Administrative database analysis is an efficient tool to track 
epidemiologic and medical picture in patients with AF, which poses a significant 
burden in term of incidence, mortality and costs.
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objeCtives: The most common infections due Streptococcus pneumoniae are: otitis, 
Pneumonia, meningitis and sepsis. The aim of this study was to estimate the direct 
and indirect costs of pneumococcal diseases, in population under 5 years old in 
Colombia. Methods: Direct costs were determined from 2 sources: costs informa-
tion for 2012 from a Health Medical Organization (HMO) with national coverage and 
the construction of cases-type based on clinical practice guidelines, through bottom-
up methodology: the generating cost events were identified, validated with medi-
cal experts and valued according to tariff manual SOAT 2013. Indirect costs were 
related to mortality and sequelae caused by pneumococcal diseases. Mortality was 
estimated in terms of years of potential life lost (YPLL) based on the YPLLipc model 
(Gardner and Sanborn). Sequelae were measured in life years saved: disability-
adjusted life years and the years of life lost to premature death. The cost estimation 
was done from the perspective of third-party payer. Costs were expressed in 2013 
Colombian pesos (~1927 Colombian Peso per 1 USD). Results: Taking into account 
the HMO information, the average cost of medical attention for Acute Otitis Media 
was $150,274 per outpatient case and $1,514,030 per inpatient case, for pneumonia 
$201,969 per outpatient case and $2,238,235 per inpatient case, for meningitis and 
sepsis $371,006 per outpatient case and $7,446,978 per inpatient case, for hearing 
loss $821,857 and for mastoiditis $206,473. Taking into account the cases-type infor-
mation, the average cost of medical attention for Acute Otitis Media was $109,386 
per initial case and $890,296 per recurrent case, for pneumonia $569,643 per mild 
case and $4,310,895 per severe case, for meningitis and sepsis $10,792,183 per case, 
for hearing loss $1,323,775 and for mastoiditis $535,692. The costs of YPLL were 
$12,014,669. ConClusions: Pneumococcal diseases cause a high economic impact 
on public health resources, due the incidence of diseases.
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objeCtives: PA costs have increased during the last years, due to an increment 
in the number of affected patients. Our goal was to establish the profile and costs 
of PA in a health care plan in Brazil. Methods: We searched the HP database in 
order to identify patients with psychiatric conditions. This HP has 364 000 users. 
We identified 569 patients that received psychiatric care during a 22-month period 
(January 2012-0ctober 2013). For each patient, we identified the resources used and 
the costs associated to them. Results: Psychiatric care was responsible for 3.3% 
of all medical consultations performed in the HP and 4,955 hospitalizations, with 
a total cost of R$ 3 753 000 (US$ 1 563 000) (mean cost of R$ 4 560 (US$ 2 041) per 
patient). The most common diagnoses were substance abuse (ICD codes F10 to F19) 
and schizophrenia (ICD F20). Ancillary fees were responsible for 94% of total costs. 
Medications represented 7% of them. Antipsychotics drugs were responsible for 60% 
of the medication costs. ConClusions: PA is associated with a high cost in Brazil. 
Most costs are due to hospital fees.
PHS38
CoSt burDen of CHroniC Pain in a large integrateD DeliverY SYStem 
in tHe uniteD StateS
Lamerato L1, Dryer R1, Mardekian J2, Hegeman-Dingle R2, Park PW2, Zlateva G2
1Henry Ford Health System, Detroit, MI, USA, 2Pfizer, Inc., New York, NY, USA
objeCtives: Chronic pain is common and persistent in the population with over 
a third of US adults affected, many with disability and quality of life issues. Pain 
management is a substantial cost burden to the health care system We sought to 
determine the prevalence and burden of pain within a large integrated health care 
delivery system in the US. Methods: Administrative databases pertaining to Henry 
Ford Health Systems (HFHS) patients were used to identify a cohort of adult persons 
with one or more of 25 pain conditions of interest in 2010 using ICD-9-CM diagnosis 
codes. Chronic pain was defined as at least two physician encounters at least 30 days 
apart. Data on prescription drug usage, hospitalizations, emergency room visits, 
physician encounters and total costs of care were obtained for a period of one year 
prior through one year after the index encounter for pain in 2010 to characterize 
resource utilization. Analyses were performed using SPS V 19.0. Results: 44% of 
persons enrolled in the health plan had at least one pain encounter with 14% meet-
ing the defined criteria for chronic pain. The conditions with the highest prevalence 
were joint pain, limb pain, and back pain. The study population also had a high 
prevalence of non-pain conditions including diabetes, chronic pulmonary disease, 
and renal disease. The overall medical costs for the patients with prevalent chronic 
pain conditions increased 24% in the post-period (average $22,639 vs. $31,692). The 
most costly conditions included diabetic neuropathy and multiple sclerosis and 
the greatest cost increases were observed for neuralgia, gout, and abdominal pain. 
Significant cost drivers included older age, presence of multiple comorbidities, and 
low body mass index. ConClusions: Chronic pain was a relatively frequent reason 
for health care service provision in HFHS and is associated with significant year-
on-year increase in medical costs.
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objeCtives: Information on costs is critical to public health policy decision-making 
about prevention strategies, but is sparse in low-income countries. We conducted a 
prospective multi-site survey of persons hospitalized in public and private facilities 
with acute respiratory infection (ARI) in northern India to estimate the costs of ARI 
episodes. Methods: Convenience samples of patients hospitalized with ARI were 
recruited at 9 public and 15 private health care facilities in the National Capital 
Region and Srinagar. Face-to-face surveys were conducted with participants upon 
admission to collect data on out-of-pocket costs of hospitalization, consultation, 
medications, diagnostics, transportation and lodging. Follow-up telephone surveys 
were conducted 2 weeks post-discharge to collect additional information including 
missed work and costs incurred after hospitalization. Out-of-pocket costs in public 
facilities were supplemented with WHO-CHOICE estimates. Missed worked days 
were valued on per capita national income (68,748 Indian Rupees). Results: During 
September, 2012-March, 2013, 452 hospitalized ARI patients were enrolled (325 in 
public and 126 in private health facilities). Median total costs of hospitalized ARI 
in public facilities was 7,633 (IQR 4, 875-13,793) Indian Rupees (INR) [US$122 (IQR 
$78-221)] and in private facilities INR 13, 598 (IQR 8,993-22,924) [US$218 (IQR $144-
367)]. The median length of stay was 7 days (IQR 5-11 days) in public facilities and 4 
days (IQR 3-5) in private facilities. The indirect cost (defined as cost of missed work 
days) accounted for 16% of total cost in private facilities and 25% in public facilities. 
Median total cost of ARI for inpatients was 11% of annual per capita income in public 
institutions and 20% in private institutions. ConClusions: ARI episodes result-
ing in hospitalizations are expensive and could be higher if more than one episode 
occurs per year. The cost and benefit of proven strategies to reduce the burden, such 
as influenza and pneumococcal vaccination should be evaluated.
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objeCtives: Urticaria is a dermatological condition characterized by a vascular 
reaction of the upper dermis. The objective of this analysis was to assess the eco-
nomic burden of urticaria from a large population based-study. Methods: The 
study population was identified through the DENALI data warehouse of the Italian 
Lombardy Region: with a probabilistic linkage DENALI matches demographic, clinical 
and economic data of different Health care Administrative databases. We detected 
all subjects who were hospitalized for idiopathic urticaria (ICD-9 CM: 708.1) or other 
specified urticaria (ICD-9 CM: 708.8) during the period 2000–2011. The first hospital 
admission date was used as index date. We estimated health care costs (hospitaliza-
tions, drugs and outpatient examinations/visits) per patients-year from the National 
Health Service’s perspective. Results: During the study period, 7,864 subjects (63.2% 
female) experienced at least one hospital admission for idiopathic urticaria or other 
specified urticaria. Subjects had a median(min-max) age of 40.9(0.0-97.1); 35.4(0.1-
97.1) and 42.4(0.0-97.1) years for idiopathic and other specified urticaria, respectively. 
The overall cost during the index year was around 2,100€ /patient-years, with no sig-
nificant differences between types of urticaria. From the 6th to the 1st year before the 
index event there was a slightly increase in costs: from 950€ /patient-years to 1,400€ /
patient-years. The overall cost remained stable for the next 5 years after the event 
(1,200€ /patient-years). Hospitalization represented the main driver of the overall cost: 
61% before, 73% during, and 53% after the index event. The most prescribed therapies 
were antihistamines for systemic use, antibacterials and corticosteroids for systemic 
use, with a peak in the month of the index event; the prescriptions of corticosteroids 
as dermatological preparation were more frequent in the month preceding the hospi-
talization. ConClusions: The economic burden of urticaria was mainly attributable 
to the index hospitalization, which led to higher costs after the index event. Detailed 
analysis are allowed by administrative data.
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objeCtives: Atrial Fibrillation (AF) is the most common type of heart rhythm disor-
der, with a prevalence of 0.5% in the adult population. It causes a significant increase 
of cardiovascular complications and reduction of long-term survival. The objective 
of this analysis was to assess the epidemiologic and economic burden of AF from 
a large population based-study. Methods: The study population was identified 
through the DENALI data warehouse of the Italian Lombardy Region: with a proba-
bilistic linkage DENALI matches demographic, clinical and economic data of dif-
ferent Health care Administrative databases. The study population was made by all 
subjects who, during the period January 2000–December 2010, were hospitalized for 
AF and flutter (ICD-9-CM: 427.3) or received ablation of heart tissue (ICD-9-CM: 37.33 
and 37.34) and/or conversion of cardiac rhythm (ICD-9-CM: 99.61,99.62, 99.69). The 
first hospital admission date was used as index date. We estimated incidence, mor-
tality and health care costs (hospitalizations, drugs and outpatient examinations/
visits) per patient-year from the National Health Service’s perspective. Results: 
During the study period, around 510,000 subjects (50.2% male) were detected, cor-
responding to 5 AF cases on 1,000 Lombardy inhabitants per year. Subjects had 
median(min-max) age of 74(0-110) years. According to the CHADS score, 62.8% and 
15.6% of the study population had a moderate and high risk of stroke, respectively. 
The overall mortality rate (x100 person-years) was 9.9, increasing significantly with 
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objeCtives: Incremental health care resource utilization associated with autoso-
mal dominant polycystic kidney disease (ADPKD) was estimated across two sub-
groups; individuals with ADPKD and end-stage renal disease (ESRD) and those with 
ADPKD but without ESRD. Methods: Study data were from a large administrative 
claims and enrollment database. Individuals 18 y/o or older, enrolled in tracked 
health plans for 12 months from April 1, 2011 through March 31, 2012, and with an 
ICD-9-CM diagnosis code for “polycystic kidney, autosomal dominant” (753.13) or 
for “polycystic kidney, unspecified type (753.12) were identified as having ADPKD, 
and linked one-to-one with individuals without ADPKD on age and gender. ESRD 
was identified by presence of ICD-9-CM code 585.6. Zero-inflated negative bino-
mial models estimated incremental hospitalizations, hospital days, outpatient 
visits, and emergency room visits for each sub-group, adjusting for age, gender, 
Charlson co-morbidity index, cardiovascular disease, diabetes and geographical 
region. Results: A total of 3,844 individuals with ADPKD who satisfied selection 
criteria were linked one-to-one with 3,844 individuals without ADPKD. Among per-
sons with ADPKD, 644 had a diagnosis of ESRD. The sample was 53% female and 
55% were between 45 to 64 years old. Incremental mean (standard error) resource 
utilization associated with ADPKD with ESRD as compared to persons without 
ADPKD was 0.35 (0.052) or 35 additional hospitalizations per 100 patients, 2.5 (0.42) 
or 250 hospital days per 100 patients, and 24.0 (1.2) or 2,400 outpatient visits per 100 
patients. Incremental mean (standard error) resource utilization associated with 
ADPKD but without ESRD as compared to persons without ADPKD was 0.065 (0.028) 
or 6.5 additional hospitalizations per 100 patients, 0.5 (0.091) or 50 hospital days per 
100 patients, and 4.4 (0.41) or 440 outpatient visits per 100 patients. ConClusions: 
ADPKD was associated with incrementally greater health care resource utilization 
even before patients reached ESRD.
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objeCtives: This study evaluated treatment patterns and costs among patients 
with pancreatic cancer (PC). Methods: A retrospective study analyzed data span-
ning January 2008-June 2012 from 3 large integrated claims databases. Adult patients 
with a diagnosis of PC (ICD-9 157.xx) were included if they had a minimum eligibility 
of 12 months prior and 3 months following their first PC diagnosis and had no diag-
nosis of cancer in the pre-period. Patients were categorized as having exocrine PC 
(ICD-9 157.0-157.3; 157.8-157.9), endocrine PC (ICD-9 157.4), or metastatic-exocrine 
PC (ICD-9 157.0-157.3; 157.8-157.9, 196.xx-199.xx). Treatment patterns, health care 
resource use, and all-cause costs (2012 USD) were evaluated after cancer diagno-
sis. Results: There were 2901, 6119, and 464 patients in each of the 3 databases 
meeting all inclusion criteria, respectively. The majority of patients had exocrine PC 
(97%-98%), with 40%-76% having metastatic disease. Patients were on average 60.3-
64.5 (±11.3-14.0) years of age and 43%-52% were female. No treatment was received 
by 35%-55% of patients, 36%-55% of patients received chemotherapy ± radiation 
and/or surgery, and 9%-10% received radiation and/or surgery without chemother-
apy. Second and third-line chemotherapy was received by 17%-32% and 9%-17% 
of patients, respectively. Among those with exocrine PC, patients with metastatic 
disease experienced an average of 0.25-0.31 inpatient, 2.3-2.9 office, 3.0-4.0 other 
outpatient visits and received 4.2-5.1 prescriptions per month vs 0.09-0.11 inpatient 
visits, 1.3-1.7 office visits, 1.3-1.9 other outpatient visits and 3.2-4.1 prescriptions per 
month in those without metastatic disease. Total monthly costs averaged $9,478-
$12,042 and $1,022-$3,084 in patients with and without metastatic disease, respec-
tively. The majority of costs were attributable to medical services ($7,977-$11,212 and 
$697-$2,852, respectively), with pharmacy costs contributing to a small proportion 
of the total costs ($830-$1,501 and $232-$326, respectively). ConClusions: Health 
care resource utilization and costs are highest among those with metastatic PC, 
totaling as much as $12,042 per month.
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objeCtives: In 2013 a change in WHO guidelines increased the number of people 
recommended to start antiretroviral treatment (ARVs) from 16 to 28 million world-
wide; at present around 10 million are enrolled in care. Additionally the number 
of people requiring second line antiretrovirals (ARVs) is increasing. Much of this 
burden is in Sub Saharan Africa (SSA). The Infectious Diseases Institute (IDI) in 
Kampala, Uganda runs a clinic of 8000 patients; some of these have been on ARVs 
for > 10 years. The objective of this study was to analyze actual costs of different 
patient subgroups per year at IDI. Methods: We use a fully digitalized electronic 
patient management system (ICEA), which records individual patient data includ-
ing all visit information. We linked ICEA to Navision accountancy software, in order 
to determine the actual cost of patient care from October 2012-October 2013. The 
analysis was conducted from a provider perspective. We calculated the average cost 
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objeCtives: Estimate direct medical costs of selected acute complications in 
patients with non-valvular atrial fibrillation (NVAF) at the Social Security (EsSalud) 
in Peru. Methods: The electronic database of EsSalud´s reference hospital: Hospital 
Nacional Guillermo Almenara Irigoyen (HNGAI) was used to identify the study popu-
lation. International Classification of Diseases (ICD) 10 codes were used to identify 
patients with NVAF and select complications of AF. Complications of interest are: 
ischemic stroke, hemorrhagic stroke, systemic embolism and myocardial infarction. 
Stroke events were classified by severity as mild, moderate, severe or fatal. All cases 
from 2011 -2012 meeting the inclusion criteria were reviewed. Patient level data from 
clinical charts was extracted to estimate resource utilization per patient per event. 
Costs were estimated using EsSalud´s 2013 tariffs manual and expressed per patient 
in 2013 USD. Results: Ischemic stroke costs were estimated at $1,259, $1,818, $ 4,910, 
and $2,829.19 for mild, moderate, severe and fatal events, respectively. Hemmorhagic 
stroke were estimated at $1,707, $2,419, $11,991 and $2,111 for mild, moderate, severe 
and fatal event, respectively. Systemic embolism and myocardial infarction were esti-
mated to cost $1,707 and $1,703 respectively. ConClusions: For AF patients within 
EsSalud, hemorrhagic stroke costs are higher than those estimated for ischemic 
stroke. As expected, costs increase as the severity of the event increase. These cost 
estimates can be used as patient-level costs inputs for economic model analysis of 
AF and its complications, from the perspective of EsSalud in Peru.
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objeCtives: To describe Health Care Pathway and cost evaluation of patients with 
osteoporosis. Methods: From ARNO Observatory, an Italian population database 
which provides comprehensive data referred to patient as: drug prescription, hospi-
tal discharges, imaging, lab tests and diagnostic examination, we analyzed a cohort 
of 185.489 subjects with osteoporosis in year 2011. A group without osteoporosis, 
matched by age, gender and LHU was compared to estimate differences in health 
costs and burden of disease. Results: On a population of 5,313,167 over 40 years, 
we identified 185,489 patients treated with osteoporosis drugs (prevalence 3.5%). 
Prevalence rate is higher in female than male (6.1% vs 0.1%), modal value on 70-79 
years. The average yearly cost/patient is 2.329€ , 53% more than pair-matched group. 
This cost is due for 38.4% to drugs (31% specific drugs, 69% others), 42.8% to hos-
pitalization and 18.8% to lab tests and diagnostic examinations. Most common 
specific drugs are bisphosphonates (81%), strontium ranelatum (21%), parathy-
roid hormone (1.2%) and SERMs (0.9%). A considerable percentage (24.8%) did not 
received vitamin D supplements in association. Compared to control group, patients 
with osteoporosis received more drugs expression of higher comorbidity (corticos-
teroids +70%, nervous system drugs +42%, PPI +33%) and were more frequently 
hospitalized, beyond fractures, for arthritis (+99%, p< 0.01) and chronic bronchitis 
(+52%, p< 0.01). Less than 50% of patients controlled their serum calcium levels in 
the last three years, 32% performed a densitometry and less than a fifth a radiog-
raphy. ConClusions: A big data infrastructure is a valid instrument to evaluate 
patient care pathways, monitor the good practice of treatment and estimate cost 
of illness. In a large community setting of osteoporotic patients, the lack of supple-
ment of vitamin D undermines the effectiveness of the specific pharmacological 
treatment. Despite low diagnostic approach, patients cost as much to the National 
Health System especially due to their frequent co-morbidities.
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objeCtives: Juvenile Idiopathic Arthritis (JIA), Ankylosing Spondylitis (AS), and 
Psoriatic Arthritis (PA) are rheumatic diseases which destroy articulations and limit 
their functions. The evolution of these conditions cause important physical impair-
ment, which leads to disability, work loss, self-sufficiency, and QoL deterioration, 
among others. The objective is to estimate the economic impact of three rheumatic 
diseases: Juvenile Idiopathic Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis 
during 2011 using registries of the main Social Security Institution in the country 
called Instituto Mexicano del Seguro Social (IMSS). Methods: It was review all 
registries related to the indications mentioned at different settings of care: ambula-
tory visits to GP and specialist, emergency room (ER), and hospital discharge (HD) 
of IMSS from January 1st to December 31st, 2011. Based on this information it was 
calculated the cost of care using unitary cost published by the Institution according 
to the type of service and the hospital DRG implicated. Results: In 2011 the IMSS 
provided 45,528 consultations for AS, 51% were for patients between 30-49 years-old. 
28,716 (63%) were for GP; 16,257 (36%) specialist; 555 (1%) ER, and 91 HD. For JIA, there 
were 6,285 consultations; 1,766 (28%) were for GP; 4326 (69%) for specialist; 193 (3%) 
ER, and 103 HD. For PA there were 1,587 consultations; 619 (39%) for GP; 873 (55%) 
specialist; 95 (6%) ER, and 195 HD. The costs of the three diseases at IMSS during 
2011 were: AS = US $2.94 million, JIA = US $0.68 million and PA= US $0.37 million. 
The total cost of the three was US $4 millions (ER 1US= 13MXN). ConClusions: 
These diseases affect quality of life and ability to work, considerably. Therefore, the 
cost of the three diseases might be underestimated due to productivity loss which 
is not included in the cost.
